Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1109410

The incidence of potential clinically significant drug interactions of warfarin in elderly patients


Falamić, Slaven; Horvat, Emilija; Smontara, Sanja; Kuharić, Maja; Bačić Vrca, Vesna
The incidence of potential clinically significant drug interactions of warfarin in elderly patients // 45th ESCP-NSF international symposium on clinical pharmacy: clinical pharmacy tackling inequalities and access to health care. Oslo, Norway, 5-7 October 2016
Oslo, Norveška: International Journal of Clinical pharmacy, 2017. str. 325-325 doi:10.1007/s11096-016-0404-4. (poster, međunarodna recenzija, sažetak, stručni)


CROSBI ID: 1109410 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The incidence of potential clinically significant drug interactions of warfarin in elderly patients

Autori
Falamić, Slaven ; Horvat, Emilija ; Smontara, Sanja ; Kuharić, Maja ; Bačić Vrca, Vesna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
45th ESCP-NSF international symposium on clinical pharmacy: clinical pharmacy tackling inequalities and access to health care. Oslo, Norway, 5-7 October 2016 / - : International Journal of Clinical pharmacy, 2017, 325-325

Skup
45th ESCP Symposium 45. Simpozij kliničke farmacije Europskog društva za kliničku farmaciju

Mjesto i datum
Oslo, Norveška, 05.10.2016. - 07.10.2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
drug interactions, warfarin

Sažetak
Background and objective: Warfarin is known for its interactions with many drugs. Elderly patients are particularly sensitive to warfarin interactions. To evaluate the incidence of potential drug interactions when prescribing new drugs to elderly patients on warfarin, a prospective observational study was conducted. Setting and method: Patients on warfarin older than 65 years were included and monitored for 6 months in 4 community pharmacies in Croatia. Data regarding new prescribed drugs was obtained from pharmacy records at the moment of dispensing or by patient selfreporting. The potential interacting drugs were identified using the Lexicomp Lexi- Interact Online software. Only the clinically significant (levels C, D, X of clinical significance as classified by Lexicomp Lexi- Interact Online) interactions were included in this analysis. Main outcome measures: Number of new proscribed drugs, level of interaction with warfarin, mechanism of interactions. Results: We included 157 elderly patients with an average age of73 years. In the follow-up period, new drugs were prescribed to 54 patients (34.4%). There were 79 prescriptions of new drugs and 57 (72.2%) of those were drugs with a clinically significant interaction with warfarin. There were 39 prescriptions of drugs with level C of interaction (68.4%), and 18 (31.6%) with level D. There were no drug interactions of level X. In the group with level C the most prescribed drugs were antibiotics with 26 prescriptions: amoxicillin/clavulanate 28%, clindamycin 8%, ciprofloxacin 8%, norfloxacin 8%, azithromycin 5%, cefuroxime 5%, clarithromycin 3%, doxycycline 3%. The remaining 13 prescriptions included tramadol with paracetamol 18%, rosuvastatin 5%, simvastatin 3%, fluvastatin 3%, levothyroxine 3% and torasemide 3%.The dominant mechanism of the potential interactions was pharmacokinetic. In the group with level D the most prescribed drugs were nonsteroidal anti- inflammatory drugs with 12 prescriptions— diclofenac 35%, ibuprofen 23%, indomethacin 12%. Among other drugs, 6 prescriptions were antibiotic sulfamethoxazole with trimethoprim 12%, fenofibrate 6%, miconazole 6%, and fluconazole 6%.The dominant mechanism of the potential interactions waspharmacodynamic. Conclusion: Pharmacists should actively monitor prescribing of new drugs to elderly patients on warfarin in order to reduce the risk of clinically significant drug interactions.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija



POVEZANOST RADA


Profili:

Avatar Url Vesna Bačić Vrca (autor)

Avatar Url Slaven Falamić (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Falamić, Slaven; Horvat, Emilija; Smontara, Sanja; Kuharić, Maja; Bačić Vrca, Vesna
The incidence of potential clinically significant drug interactions of warfarin in elderly patients // 45th ESCP-NSF international symposium on clinical pharmacy: clinical pharmacy tackling inequalities and access to health care. Oslo, Norway, 5-7 October 2016
Oslo, Norveška: International Journal of Clinical pharmacy, 2017. str. 325-325 doi:10.1007/s11096-016-0404-4. (poster, međunarodna recenzija, sažetak, stručni)
Falamić, S., Horvat, E., Smontara, S., Kuharić, M. & Bačić Vrca, V. (2017) The incidence of potential clinically significant drug interactions of warfarin in elderly patients. U: 45th ESCP-NSF international symposium on clinical pharmacy: clinical pharmacy tackling inequalities and access to health care. Oslo, Norway, 5-7 October 2016 doi:10.1007/s11096-016-0404-4..
@article{article, author = {Falami\'{c}, Slaven and Horvat, Emilija and Smontara, Sanja and Kuhari\'{c}, Maja and Ba\v{c}i\'{c} Vrca, Vesna}, year = {2017}, pages = {325-325}, DOI = {10.1007/s11096-016-0404-4.}, keywords = {drug interactions, warfarin}, doi = {10.1007/s11096-016-0404-4.}, title = {The incidence of potential clinically significant drug interactions of warfarin in elderly patients}, keyword = {drug interactions, warfarin}, publisher = {International Journal of Clinical pharmacy}, publisherplace = {Oslo, Norve\v{s}ka} }
@article{article, author = {Falami\'{c}, Slaven and Horvat, Emilija and Smontara, Sanja and Kuhari\'{c}, Maja and Ba\v{c}i\'{c} Vrca, Vesna}, year = {2017}, pages = {325-325}, DOI = {10.1007/s11096-016-0404-4.}, keywords = {drug interactions, warfarin}, doi = {10.1007/s11096-016-0404-4.}, title = {The incidence of potential clinically significant drug interactions of warfarin in elderly patients}, keyword = {drug interactions, warfarin}, publisher = {International Journal of Clinical pharmacy}, publisherplace = {Oslo, Norve\v{s}ka} }

Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font